Bad Homburg vor der Höhe

Fresenius Kabi Introduces First-Ever Generic for Foscavir® (Foscarnet Sodium) Injection

Retrieved on: 
Monday, March 15, 2021
Health, FDA, Other Health, Clinical trials, Research, Science, Pharmaceutical, Bad Homburg vor der Höhe, Fresenius, Societates Europaeae, Foscarnet, Companies, Germany, Life sciences, Bidiphar, Foscarnet Sodium Injection, Fresenius Kabi

Fresenius Kabi Foscarnet Sodium Injection is available in 6000 mg / 250 mL bottle.

Key Points: 
  • Fresenius Kabi Foscarnet Sodium Injection is available in 6000 mg / 250 mL bottle.
  • View the full release here: https://www.businesswire.com/news/home/20210315005083/en/
    Fresenius Kabi has launched the first generic for Foscavir (Foscarnet Sodium Injection).
  • Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
  • To learn more about Fresenius Kabi, including its expanding U.S. centers for pharmaceutical research, manufacturing and distribution, please visit www.fresenius-kabi.com/us .

Fresenius Medical Care Asia Pacific Continues to Forge Organization-Wide Inclusion and Diversity

Retrieved on: 
Monday, March 8, 2021
Managed care, Health, Practice Management, Other Health, Bad Homburg vor der Höhe, Fresenius, Germany, Companies

This initiative is part of the global Inclusion & Diversity efforts from Fresenius Medical Care.

Key Points: 
  • This initiative is part of the global Inclusion & Diversity efforts from Fresenius Medical Care.
  • Fresenius Medical Care is committed to serving all its patients across the globe with the same level of care and devotion to their health and wellbeing.
  • This accelerates innovation, fosters employee satisfaction, and in turn drives financial outcomes, said Harry de Wit, CEO & President of Fresenius Medical Care Asia Pacific.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

DGAP-News: publity AG: Commercial property sold in Bad Homburg with Deutsche Bahn as main tenant

Retrieved on: 
Wednesday, March 3, 2021
States of Germany, Hesse-Nassau, Hesse, Bad Homburg vor der Höhe, Hochtaunuskreis, Frankfurt, Homburg (Saar) Hauptbahnhof, Taunus, Rhine-Main S-Bahn, Transport in Frankfurt

Frankfurt, 03.03.2021- publity AG (Scale, ISIN DE0006972508, "publity") has successfully sold an office property in Bad Homburg in its position as asset manager.

Key Points: 
  • Frankfurt, 03.03.2021- publity AG (Scale, ISIN DE0006972508, "publity") has successfully sold an office property in Bad Homburg in its position as asset manager.
  • The office building provides a total lettable area of just under 5,200 square metres and is situated in a centrally located commercial area of Bad Homburg, just outside Frankfurt/Main.
  • publity acquired the property in 2017 and has since successfully developed it; the main tenants include Deutsche Bahn and a major air conditioning manufacturer.
  • The office property is in the asset portfolio of GORE German Office Real Estate AG (ISIN DE000A0Z26C8), an indirect subsidiary of publity AG.

Fresenius Medical Care North America's Products Division Earns J.D. Power Certification for Customer Service

Retrieved on: 
Wednesday, February 24, 2021
Bad Homburg vor der Höhe, Medicine, Clinical medicine, Membrane technology, Private providers of NHS services, Health care, Fresenius Medical Care, Dialysis, Fresenius

This certification is the first of its kind for a dialysis company and recognizes an "outstanding customer service experience."

Key Points: 
  • This certification is the first of its kind for a dialysis company and recognizes an "outstanding customer service experience."
  • "It is especially rewarding to earn this certification after our customer service team delivered such essential service to providers on the frontlines of the pandemic."
  • The Renal Therapies Group Customer Service team assists home patients and dialysis facilities throughout the United States in ordering dialysis supplies.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

DGAP-News: Fresenius Medical Care AG & Co. KGaA published form 20-F for the fiscal year 2020

Retrieved on: 
Wednesday, February 24, 2021
Bad Homburg vor der Höhe, Private providers of NHS services, Fresenius Medical Care, Fresenius, Germany, Membrane technology, Health care, Dialysis

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Annual Results

Key Points: 
  • DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Annual Results
    Fresenius Medical Care AG & Co. KGaA published form 20-F for the fiscal year 2020
    The issuer is solely responsible for the content of this announcement.
  • The company also published a Facts & Figures 2020 website at factsandfigures.fmc-ag.com to provide an overview of the key financial figures for the fiscal year 2020.
  • Through its network of 4,092 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 346,553 patients around the globe.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

DGAP-News: Fresenius Medical Care AG & Co. KGaA achieves 2020 targets, expects significant COVID-19 impact in 2021 and confirms 2025 outlook

Retrieved on: 
Tuesday, February 23, 2021
Bad Homburg vor der Höhe, Private providers of NHS services, Fresenius, Societates Europaeae, Germany, Companies

In 2020, Fresenius Medical Care provided more than 14% of its dialysis treatments in the U.S. in a home setting.

Key Points: 
  • In 2020, Fresenius Medical Care provided more than 14% of its dialysis treatments in the U.S. in a home setting.
  • This additionally affects the utilization of Fresenius Medical Care's clinic network and thereby limits the ability to mitigate fixed cost and wage inflation.
  • Fresenius Medical Care confirms its 2025 targets that are based on the Company's mid-term strategy.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Cove Capital Acquires Fresenius Medical Care Dialysis Facility in New Orleans

Retrieved on: 
Thursday, February 4, 2021
Bad Homburg vor der Höhe, Private providers of NHS services, Fresenius, Societates Europaeae, Germany, Dialysis, LaPlace, Louisiana, Health care

LOS ANGELES, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Cove Capital Investments, LLC (Cove Capital) and its affiliates are pleased to announce the acquisition of the Fresenius Medical Care dialysis facility located at 704 Belle Terre Blvd., LaPlace, Louisiana 70068 (the Property).

Key Points: 
  • LOS ANGELES, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Cove Capital Investments, LLC (Cove Capital) and its affiliates are pleased to announce the acquisition of the Fresenius Medical Care dialysis facility located at 704 Belle Terre Blvd., LaPlace, Louisiana 70068 (the Property).
  • Specifically, the Property constitutes the single asset in Cove Capitals latest medical net-lease investment offering: Cove LaPlace Dialysis 26 DST, a regulation D, Rule 506c private placement.
  • As Cove Capital continues to grow, the company remains unrelenting in its dedication to providing 1031 investors with an assortment of quality net-leased properties with what we believe to be strong and enduring tenants, including tenants in the medical industry such as Fresenius Medical Care.
  • Accordingly, the Property, and its accompanying offering, represent the latest endeavor of Cove Capital into the medical net-lease offering space and serve to grow the ever-expanding line of DST offerings Cove Capital offers to investors.

Vifor Pharma to propose Dr Alexandre LeBeaut as Board member

Retrieved on: 
Tuesday, February 2, 2021
Biotechnology, Pharmaceutical, Health, Cardiology, Vifor Pharma, Bad Homburg vor der Höhe, Companies, Germany, Etienne Jornod, Draft:Rice Powell

Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.

Key Points: 
  • Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.
  • Jacques Theurillat, Chairman of Vifor Pharma, commented: We are very pleased to nominate Alexandre LeBeaut for election to the Vifor Pharma Group Board of Directors.
  • Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

DGAP-News: Fresenius Medical Care AG & Co. KGaA anticipates significant negative impact on 2021 net income from accelerated COVID-19 related excess mortality of dialysis patients; confirms mid-term targets

Retrieved on: 
Monday, February 1, 2021
Bad Homburg vor der Höhe, Private providers of NHS services, Fresenius, Societates Europaeae, Germany, Membrane technology, Health care, Dialysis

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast

Key Points: 
  • DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast
    Fresenius Medical Care AG & Co. KGaA anticipates significant negative impact on 2021 net income from accelerated COVID-19 related excess mortality of dialysis patients; confirms mid-term targets
    The issuer is solely responsible for the content of this announcement.
  • Despite those negative impacts of the COVID-19 pandemic, Fresenius Medical Care has achieved - based on the preliminary and unaudited financials - its revenue target and slightly exceeded its net income [1] targets for 2020 [2] .
  • Through its network of 4,073 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 349,167 patients around the globe.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius Medical Care North America Enhances Nationwide Distribution of Home Dialysis Machines and Supplies with Descartes Last Mile Delivery Solution

Retrieved on: 
Monday, February 1, 2021
Articles, Philosophy, Philosophers, Bad Homburg vor der Höhe, Private providers of NHS services, Fresenius Medical Care, Fresenius, René Descartes, Last mile, Childbirth, Health care, Chronic condition

Descartes last mile delivery solution provides an end-to-end platform for home and last mile delivery operations.

Key Points: 
  • Descartes last mile delivery solution provides an end-to-end platform for home and last mile delivery operations.
  • Using advanced continuous optimization technology, Descartes last mile delivery solution takes committed appointments and improves route productivity, which generates additional delivery capacity and reduces costs.
  • Were pleased to help Fresenius Medical Care North America make the distribution of its services and equipment more responsive and efficient, said James Wee, Vice President at Descartes.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.